Literature DB >> 32652468

Candidate biomarker assessment for pharmacological response.

William C Reinhold1, Fathi Elloumi2, Sudhir Varma3, Jacques Robert4, Gordon B Mills5, Yves Pommier6.   

Abstract

Using the information from our CellMiner (https://discover.nci.nih.gov/cellminer/) and CellMinerCDB (https://discover.nci.nih.gov/cellminercdb/) web-based applications, we identified 3978 molecular events with significant links to pharmacological response for genes that are either targets, biomarkers, or have established causal linkage to drugs. Molecular events included DNA copy number, methylation and mutation; and transcript; and whole or phospho-protein expression for the NCI-60 human cancer cell lines. While all forms of molecular data were informative in some (gene-drug) pairings, the type of significantly linked molecular events was found to vary widely by drug. Some forms of molecular data were found to have more frequent significant correlation than others. Leading were phosphoproteins as measured by antibody (31%), followed by transcript as measured by microarray (16%), and total protein levels as measured by mass spectrometry or antibody (14%). All other measurements ranged between 5 and 11%. Data reliability was underscored by concordant results when using differing drugs with the same targets, as well as different measurements of the same molecular parameter. The significance of correlations of the various molecular parameters to the pharmacological responses provides functional indication of those parameters that are biologically relevant for each gene-drug pairing, as well as comparisons between measurement types. Published by Elsevier Inc.

Entities:  

Year:  2020        PMID: 32652468      PMCID: PMC7348063          DOI: 10.1016/j.tranon.2020.100830

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  20 in total

1.  Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.

Authors:  Samit Patrawala; Igor Puzanov
Journal:  Future Oncol       Date:  2012-05       Impact factor: 3.404

Review 2.  Targeting Topoisomerase I in the Era of Precision Medicine.

Authors:  Anish Thomas; Yves Pommier
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

Review 3.  Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Authors:  Junko Murai; Anish Thomas; Markku Miettinen; Yves Pommier
Journal:  Pharmacol Ther       Date:  2019-05-23       Impact factor: 12.310

4.  A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

Authors:  Agustin A Garcia; Michael W Sill; Heather A Lankes; Andrew K Godwin; Robert S Mannel; Deborah K Armstrong; Robert L Carolla; Marcia K Liepman; Nick M Spirtos; Edgar G Fischer; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2011-10-28       Impact factor: 5.482

5.  DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?

Authors:  William C Reinhold; Anish Thomas; Yves Pommier
Journal:  Trends Cancer       Date:  2017-01

6.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

Review 7.  Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

Authors:  Yoshinori Ito; Nahomi Tokudome; Tsutomu Sugihara; Shunji Takahashi; Kiyohiko Hatake
Journal:  Breast Cancer       Date:  2007       Impact factor: 4.239

8.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays.

Authors:  Satoshi Nishizuka; Lu Charboneau; Lynn Young; Sylvia Major; William C Reinhold; Mark Waltham; Hosein Kouros-Mehr; Kimberly J Bussey; Jae K Lee; Virginia Espina; Peter J Munson; Emanuel Petricoin; Lance A Liotta; John N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

9.  CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.

Authors:  Vinodh N Rajapakse; Augustin Luna; Mihoko Yamade; Lisa Loman; Sudhir Varma; Margot Sunshine; Francesco Iorio; Fabricio G Sousa; Fathi Elloumi; Mirit I Aladjem; Anish Thomas; Chris Sander; Kurt W Kohn; Cyril H Benes; Mathew Garnett; William C Reinhold; Yves Pommier
Journal:  iScience       Date:  2018-12-12

Review 10.  Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review.

Authors:  Austin Greco; Danish Safi; Umang Swami; Tim Ginader; Mohammed Milhem; Yousef Zakharia
Journal:  Cancers (Basel)       Date:  2019-12-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.